



香港城市大學
City University of Hong Kong

BEVATECH: --- *COUNTERFEIT TEST FOR BEVACIZUMAB*



CITYU-HK IGEM TEAM 2024

Bevacizumab (©Avastin)


Treating 2.2+ Millions Cancer Patients Annually

Covering Different Tumour Types:

Lungs, Brain, Colorectal, Ovaries, Cervical, Kidneys



Market Size of ©Avastin



\$5.7B

Total Market Size

\$=USD

Source: IQVIA 2023

Developing Countries Account for More Than 20% of Counterfeit Drugs



Cases of Counterfeit ©Avastin

Medical News & Perspectives

March 6, 2013

FDA Warning: New Batch of Fake Bevacizumab Found

Bridget M. Kuehn, MSJ

JAMA. 2013;309(9):864. doi:10.1001/jama.2013.1719

A counterfeit version of the injectable cancer drug bevacizumab that may contain no active ingredient has been distributed to clinics in the United States, according to a US Food and Drug Administration (FDA) alert to physicians. The incident is the latest in a string of cases in which foreign drug distributors have sold counterfeit medications to US medical practices.

Warning over ‘counterfeit’ drugs that blinded diabetes patients in Pakistan

A total of 68 diabetics completely lost their vision after being injected with, what is thought to be, a bogus version of a well-known drug

Haroon Janjua, IN ISLAMABAD


29 September 2023 • 12:15pm

“Incidents of loss of vision in diabetic patients have been reported following treatment with Altered/Dispensed/Diluted Avastin injection,” the Drug Regulatory Authority of Pakistan (DRAP) said in a statement.


A rapid, affordable, and precise solution is needed

Causes of Counterfeit Problems in Developing Economies

- **Poor Trade Regulation**
- **Lack of Quality Control**
- **Insufficient Testing Facilities**
- **Corruption**




Conventional Method vs Our Solution for Drug Validation



Costly, Time Consuming, Require Particular Devices and Operator

Our Method




Low Cost, Rapid, and No Lab Required



Our Solution




Express Test for the Validation of Bevacizumab (©Avastin)

- ✓ Low-cost
- ✓ Rapid results
- ✓ Simple to use
- ✓ No laboratory equipment
- ✓ Large-scale manufacturing



\$1.5 per unit

Our Product




Computer Modeling

Lab Test & Optimization


Product Development

Final Product

Our Product is Simple to Use



Fake Drug (Two Lines)



Valid Drug (One Line)


Distribution Channels




BEVATECH




**Pharmaceutical
Companies**



**Research
Institutions**



**Hospitals and
Diagnostic Centres**





NGOs

Our Product vs Competitors

Company	Technology	Low Cost	Rapid	User-friendly	Remote-use	Mass Distribution
 BEVATECH	Lateral Flow Assay test strip	✓	✓	✓	✓	✓
 SCANNER	Spectroscopy	✗	✓	✗	✓	✗
 AEGATE	Drug packaging authentication	✗	✓	✓	✗	✗
 TruTag TECHNOLOGIES	Barcodes for verification	✗	✗	✗	✗	✗

Competitive Landscape







Research




Prof. Maria Babak



Artem Stetoi



Maryana Yarshova



Danis Bekmansurov



Egor Matnurov

R&D

Advisors



Prof. Oleg Kiriukhin



Oceana Wong

Entrepreneurship



Valensia Nadya



Lu Yi

Operations



Bermet Abylova



Jocelyn Madolen



Market Research



Abdul Raffay




Polina Chernova



Julia Ying



Chong Shu Pong



Darrel Hartanto



Kim Luna

Media and Marketing



Choe Hojung



Gayeon Choi



Lee Huijong




THANK YOU!



Instagram
@igem_cityu



LinkedIn
@CityU iGEM



SWOT Analysis

Strengths	Weaknesses	Opportunities	Threats
• Cost-Effective • High Specificity • High Sensitivity • User-Friendly • Rapid Results	• Regulatory Complexities • Distribution Channels	• Growing Demand for Counterfeit Drug Detection • Expanding Applications for Other Types of Drugs • Partnerships with Hospitals, Pharmaceutical Companies, and NGOs	• Public Perception and Adoption • Competition from Other Companies • Intellectual property Challenges • Regulatory Challenges

Key Partners

- **Research Institutions:** City University of Hong Kong
- **Pharmaceutical Companies:** Roche, Amgen, Pfizer, Amneal Pharmaceuticals, Celltrion, Fujifilm Kyowa Kirin Biologics, AstraZeneca, Samsung Bioepis(Samsung BioLogics)
- **NGOs:** Médecins Sans Frontières, CARE International, International Red Cross and Red Crescent Movement, BRAC, Aide et Action, Plan International, Save the Children
- **Hospitals and Diagnostic Centers:** Apollo Hospitals, Peking Union Medical College Hospital, Bumrungrad International Hospital

Value Propositions

- **Low-cost:** Only cost \$2.25 per unit
- **Rapid results:** Immediate result within 15 minutes from testing
- **Simple to use:** User-friendly design that can be used by anyone intuitively, without any expertise
- **No laboratory equipment:** Do not require any specific tools to operate
- **Large-scale manufacturing :** Able to be produced massively and distributed into different regions in high quantities.

Key Resources

- **Human Resources:** Team of scientists, researchers, and regulatory experts
- **Technology & Product Design:** Synthetic biology tools and equipment for test strip development
- **Partnerships:** Relationships with pharmaceutical companies, NGOs, hospitals, and research institutions

Key Activities

- **R&D:** Development of rapid and sensitive detection methods using modular synthetic biology
- **Regulatory Approvals:** Obtain necessary approvals for test strips in different regions
- **Manufacturing:** Production of test strips
- **Distribution:** Partner with NGOs, hospitals, and pharmacies for distribution
- **Awareness Campaigns:** Raise awareness about drug counterfeiting issues and the availability of test strips
- **Collaborations:** Work with experts and institutions to refine technology

Customer Relationships

- **B2B:** Long-term contracts with hospitals, pharmaceutical companies, and diagnostic centers
- **B2C:** Direct support and educational resources for end-users
- **NGOs:** Partnerships and collaboration on distribution and awareness campaigns

Channels

- **Direct Sales:** Through partnerships with hospitals, diagnostic centers, and pharmaceutical companies
- **Online Sales:** E-commerce platform for direct purchase by consumers in high-risk areas
- **NGO Distribution:** Leveraging NGO networks to distribute test strips in conflict zones and developing countries
- **Healthcare Conferences and Events:** Presenting at industry events to raise awareness and build relationships

Customer Segments

- **Hospitals and Diagnostic Centers:** Looking to ensure the authenticity of their medications
- **Pharmaceutical Companies:** Seeking quality control solutions
- **NGOs:** Working in regions with high rates of drug counterfeiting
- **Patients and Consumers:** Particularly in conflict zones and developing countries

Cost Structure

- **R&D Costs:** Development of detection methods (aptamer optimization) and test strips
- **Manufacturing Costs:** Production of test strips (estimated to be \$1.5)
- **Regulatory Costs:** Obtaining approvals and certifications
- **Distribution Costs:** Partnering with NGOs and shipping products
- **Marketing and Awareness:** Campaigns to raise awareness about drug counterfeiting and promote test strips

Revenue Streams

- **Sales of Test Strips:** Direct sales to hospitals, diagnostic centers, and consumers
- **Partnerships:** Revenue from collaborations with pharmaceutical companies
- **Grants and Funding:** Support from health organizations and foundations
- **Licensing:** Licensing technology to other companies or regions

Patent Applications



**Consult legal team
for patent
applications**

Patent Review

PRESENT

Q4/2024

Q1/2025

Q2/2025

Q3/2025

**Patent Research
and Guidance**

**Patent Application
US & China**

Patent Granted

